Recombinant Human Insulin-induced gene 2 protein (INSIG2)

What is INSIG2 and what is its main function?

INSIG2 (Insulin-induced gene 2) encodes an endoplasmic reticulum protein that plays a critical role in regulating cholesterol synthesis and fatty acid metabolism. It functions primarily as a negative regulator of cholesterol biosynthesis by mediating the retention of the SCAP-SREBP complex in the endoplasmic reticulum, thereby blocking the processing of sterol regulatory element-binding proteins (SREBPs) . This protein belongs to a family of oxysterol-binding proteins that interact with SCAP (SREBP cleavage-activating protein) and HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) to maintain cholesterol homeostasis in mammalian cells.

In the presence of oxysterols (oxidized derivatives of cholesterol), INSIG2 binds to SCAP, which prevents SCAP from escorting SREBPs to the Golgi apparatus for proteolytic activation. This regulatory mechanism effectively suppresses the transcription of genes involved in cholesterol and fatty acid synthesis under high sterol conditions .

How does INSIG2 differ between humans and rodents?

In rodents, two distinct INSIG2 transcripts have been identified: Insig2a and Insig2b. These two variants differ in their noncoding first exons that splice into a common second exon through the use of different promoters. While both transcripts encode identical proteins, they exhibit different regulation patterns, with Insig2a being down-regulated by insulin in rodent liver .

Interestingly, comparative analysis of human and rodent genomic sequences revealed that despite high sequence homology between the species, the INSIG2a transcript is not expressed in human liver. RT-PCR analysis confirmed that while both mRNA variants (Insig2a and Insig2b) were detected in mouse and rat liver, only the INSIG2b form was detected in human liver samples. This finding was further confirmed in human cell lines including HEK293T and HepG2, where no trace of the INSIG2a transcript was found .

What methodologies are recommended for studying INSIG2 expression?

For investigating INSIG2 expression in tissue or cell samples, the following methodological approaches are recommended:

• RT-PCR Analysis: Design primers specific to INSIG2 variants for detection of transcript expression. For human samples, focus on the INSIG2b form as it is the predominant transcript in human liver and cell lines .

• Promoter Activity Assays:

  • Clone the promoter region upstream of a reporter gene (e.g., luciferase)

  • Create serial 5′ truncations of the promoter to identify crucial regulatory regions

  • Transfect constructs into relevant cell lines (HEK293T or HepG2 have been successfully used)

  • Measure reporter activity to determine functional importance of specific regions

• Site-Directed Mutagenesis: To analyze the contribution of individual binding sites within the INSIG2 promoter, introduce specific mutations and assess their impact on promoter activity through reporter assays .

• ChIP Assay: Chromatin immunoprecipitation followed by real-time PCR can be used to verify the binding of transcription factors to the INSIG2 promoter region in vivo .

What is known about the regulation of human INSIG2 gene expression?

The human INSIG2 gene expression is regulated through several mechanisms:

• Promoter Structure: Functional promoter analysis has revealed that a 350-bp region upstream of the transcription start site is sufficient to retain full promoter activity, with the first 150 bp still retaining 40% of the promoter activity in cell lines like HEK293T and HepG2 .

• Transcription Factor Binding: The Ets family of transcription factors plays a crucial role in regulating INSIG2 expression. Particularly, site-directed mutagenesis studies have shown that mutation of Ets elements in the promoter leads to a dramatic drop in reporter activity, with the Ets-a site having the greatest effect .

• Specific Transcription Factors: Electrophoretic mobility shift assays and ChIP analyses have demonstrated that ELK1 and SAP1a (serum response factor accessory protein-1a) transcription factors bind to the Ets-a element in the human INSIG2 promoter .

• Insulin Regulation: Unlike in rodents where Insig2a is down-regulated by insulin, evidence suggests that insulin activates the human INSIG2 promoter through a process mediated by phosphorylated SAP1a .

What experimental approaches are recommended for analyzing INSIG2-SCAP interactions?

To study the interactions between INSIG2 and SCAP under various sterol conditions, researchers can employ several advanced methodologies:

• Co-Immunoprecipitation (Co-IP) Assays: This technique can be used to pull down protein complexes and analyze the interaction between INSIG2 and SCAP under different sterol conditions.

  • Express tagged versions of INSIG2 and SCAP in appropriate cell systems

  • Treat cells with different sterols, including 22-hydroxycholesterol, 24-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol

  • Immunoprecipitate one protein and detect the presence of the interacting partner by western blotting

• FRET (Förster Resonance Energy Transfer) Analysis: This technique allows for the measurement of protein-protein interactions in living cells.

  • Fuse INSIG2 and SCAP with appropriate fluorescent proteins

  • Monitor changes in FRET efficiency under different sterol conditions

  • Quantify interaction strength and dynamics in real-time

• Bimolecular Fluorescence Complementation (BiFC): This approach can visualize the spatial and temporal dynamics of protein interactions.

  • Split a fluorescent protein and fuse each half to INSIG2 and SCAP

  • When the proteins interact, fluorescence is reconstituted

  • Analyze the subcellular localization of the interaction under various sterol conditions

How can recombinant human INSIG2 protein be optimally expressed and purified for structural studies?

For structural and functional studies, high-quality recombinant INSIG2 protein is essential. Based on available information, the following protocol is recommended:

• Expression System Selection:

  • Cell-free expression systems have been successfully used to produce full-length human INSIG2 protein (amino acids 1-225)

  • Alternative systems include insect cells (Sf9, High Five) which are often suitable for membrane proteins

• Construct Design:

  • Include appropriate tags for purification (e.g., His-tag, FLAG-tag)

  • Consider codon optimization for the expression system

  • For structural studies, construct design should account for potential flexible regions that might interfere with crystallization

• Purification Strategy:

  • Use detergent screening to identify optimal solubilization conditions

  • Implement a multi-step purification approach:
    a. Affinity chromatography based on the chosen tag
    b. Size exclusion chromatography to separate aggregates
    c. Ion exchange chromatography for further purification if needed

• Quality Assessment:

  • SDS-PAGE analysis to confirm purity (≥85% purity is typically achievable)

  • Western blotting for identity confirmation

  • Mass spectrometry for accurate molecular weight determination

  • Circular dichroism to assess secondary structure integrity

What are the challenges in investigating INSIG2's role in metabolic diseases?

Investigating INSIG2's role in metabolic diseases presents several significant challenges:

• Genetic Complexity: Multiple genetic loci are linked to metabolic disorders, making it difficult to isolate INSIG2's specific contributions. Genome-wide linkage analyses have identified the locus where the INSIG2 gene is located as potentially linked to body mass index and obesity in humans .

• Polymorphic Variation Analysis: While Herbert et al. identified a genetic variant associated with obesity in the genomic region where INSIG2 is located using data from Framingham Heart Study participants, comprehensive data on human polymorphic variation in INSIG2 remains limited .

• Tissue-Specific Effects: INSIG2 may have different functions in different tissues. For instance, in type 2 diabetes and obesity, SREBP1c mRNA levels decrease in adipose tissue but are elevated in the liver of obese mice . This tissue specificity complicates the design of experiments and interpretation of results.

• Methodological Approaches:

  • Animal Models: Develop and characterize appropriate knockout or transgenic models

  • Human Genetic Studies: Design case-control studies with sufficient statistical power

  • Tissue-Specific Analysis: Implement techniques to study INSIG2 function in specific tissues

  • Integration of Multiple Data Types: Combine genetic, transcriptomic, and proteomic data

How does phosphorylation affect INSIG2's function in regulating cholesterol synthesis?

Phosphorylation plays a crucial role in modulating INSIG2's function in the regulation of cholesterol synthesis:

• Mechanism of Action: Phosphorylation of INSIG2 by PCK1 (phosphoenolpyruvate carboxykinase 1) reduces its oxysterol-binding capacity. This disrupts the interaction between INSIG2 and SCAP, promoting Golgi transport of the SCAP-SREBP complex .

• Regulatory Consequences: The phosphorylation-induced disruption of INSIG2-SCAP interaction leads to:

  • Processing of SREBPs in the Golgi apparatus

  • Nuclear translocation of processed SREBPs

  • Activation of genes involved in cholesterol and fatty acid synthesis

• Experimental Approach to Study Phosphorylation:

  • Phospho-specific antibodies can be used to detect phosphorylated INSIG2

  • Phosphomimetic mutations (e.g., serine to aspartate) can simulate constitutive phosphorylation

  • Phospho-dead mutations (e.g., serine to alanine) can prevent phosphorylation

  • Mass spectrometry can identify specific phosphorylation sites

• Physiological Context: Understanding how hormonal and nutritional signals regulate INSIG2 phosphorylation can provide insights into metabolic disorders associated with dysregulated cholesterol metabolism.

What are the latest findings regarding INSIG2 promoter regulation?

Recent research has uncovered several key aspects of INSIG2 promoter regulation:

• Ets Family Transcription Factors: The Ets family of transcription factors plays a critical role in regulating human INSIG2 expression. Specifically, SAP1a (serum response factor accessory protein-1a) has been shown to interact with the Ets-a element in the INSIG2 promoter .

• Promoter Functional Elements: Deletion analyses on 3 kb of 5′-flanking DNA of the human INSIG2 gene have revealed the functional importance of a 350-bp region upstream of the transcription start site. Within this region, a 150-bp fragment still retains 40% of the promoter activity, suggesting it contains a basal promoter region critical for INSIG2 gene expression .

• Insulin Regulation: Unlike in rodents where Insig2a is down-regulated by insulin, evidence suggests that insulin activates the human INSIG2 promoter through a process mediated by phosphorylated SAP1a. This represents an unexpected mode of regulation for INSIG2 expression in human liver .

• Experimental Techniques for Studying Promoter Regulation:

  • Reporter Assays: Using luciferase constructs with various promoter fragments

  • Chromatin Immunoprecipitation (ChIP): To verify transcription factor binding in vivo

  • Electrophoretic Mobility Shift Assays (EMSA): To analyze protein-DNA interactions in vitro

  • Site-Directed Mutagenesis: To determine the functional importance of specific binding sites

What CRISPR-Cas9 strategies are most effective for studying INSIG2 function?

CRISPR-Cas9 technology offers powerful approaches for investigating INSIG2 function in cellular systems:

• Knockout Strategies:

  • Design guide RNAs targeting early exons of INSIG2

  • Verify knockout efficiency by Western blotting and RT-PCR

  • Analyze phenotypic changes in cholesterol metabolism and SREBP processing

  • Consider potential compensatory mechanisms (e.g., upregulation of INSIG1)

• Knock-in Approaches:

  • Generate tagged versions of INSIG2 at endogenous loci for tracking protein localization

  • Introduce specific mutations to study structure-function relationships

  • Create reporter constructs to monitor INSIG2 expression in real-time

• CRISPRi/CRISPRa Systems:

  • Use CRISPR interference (CRISPRi) for targeted repression of INSIG2 expression

  • Apply CRISPR activation (CRISPRa) to enhance INSIG2 expression

  • These approaches allow for temporal control of gene expression without permanent genomic modifications

• Screening Applications:

  • Develop CRISPR screens to identify genes that interact with INSIG2

  • Design phenotypic assays based on cholesterol metabolism or SREBP processing

  • Use pooled or arrayed screening formats depending on the research question

How can contradictions in INSIG2 research data be effectively analyzed and reconciled?

When confronted with contradictory data in INSIG2 research, systematic approaches to analysis and reconciliation are essential:

• Methodological Variations:

  • Compare experimental methodologies in detail

  • Assess differences in cell types, culture conditions, and analytical techniques

  • Consider the sensitivity and specificity of detection methods

• Species-Specific Differences:

  • Recognize that INSIG2 regulation differs between humans and rodents

  • In rodents, two distinct transcripts (Insig2a and Insig2b) are expressed, while only INSIG2b is detected in human liver

  • These differences may explain some contradictions in research findings

• Tissue-Specific Effects:

  • INSIG2 function may vary across different tissues

  • In metabolic disorders, SREBP1c levels decrease in adipose tissue but increase in liver

  • Design experiments to specifically address tissue-specific mechanisms

• Statistical Analysis and Replication:

  • Apply robust statistical methods to evaluate significance

  • Consider statistical power in experimental design

  • Implement independent replication studies when contradictions arise

What quality control measures are crucial when working with recombinant INSIG2 protein?

Ensuring the quality of recombinant INSIG2 protein is essential for reliable experimental outcomes:

• Purity Assessment:

  • SDS-PAGE analysis should confirm purity of at least 85%

  • Silver staining for detecting low-level contaminants

  • Mass spectrometry for comprehensive purity analysis

• Functional Validation:

  • Binding assays with known interacting partners (SCAP, oxysterols)

  • Verification of oxysterol binding capacity with various sterols including 22-hydroxycholesterol, 24-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol

  • Confirmation of ability to mediate SCAP-SREBP retention in the endoplasmic reticulum

• Structural Integrity:

  • Circular dichroism spectroscopy to verify secondary structure

  • Thermal shift assays to assess protein stability

  • Size exclusion chromatography to detect aggregation

• Storage Stability:

  • Optimize buffer conditions to maintain protein stability

  • Determine appropriate storage temperature and freeze-thaw tolerance

  • Implement regular quality checks for long-term stored protein samples